− LIVTENCITY Is the First and Only Treatment Approved for This Indication by the EC1 − CMV Is One of the Most Common and Serious Post-transplant Infections and Can Lead to Loss of Transplanted Organ and Failure of Graft 2,3 OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) has … [Read more…]

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (“Rallybio”) (Nasdaq: RLYB) today announced the pricing of an underwritten public offering of 5,000,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3,333,388 shares of … [Read more…]

TOKYO–(BUSINESS WIRE)–Kirin Holdings Company, Limited (Kirin Holdings) and Kao Corporation (Kao) will participate in the “Wakayama Health Promotion Study” cohort study*1 led by Wakayama Medical University and compiled by the Health Promotion Research Center (HPRC), a non-profit organization, from this month. Kirin Holdings and Kao will jointly conduct research to investigate the relationship between visceral … [Read more…]

VIRGINIA BEACH, Va.–(BUSINESS WIRE)–On Tuesday, October 25th, Elysian Wellness celebrated its one year anniversary. Elysian enters its second year of business serving the Hampton Roads community by offering ketamine therapy for those suffering from depression, anxiety, PTSD, suicidal ideations, and chronic pain. Elysian Wellness is the only practice in Hampton Roads that is run exclusively … [Read more…]

Patients Were 3.1x More Likely to Reach Treatment Goals When Tested with PrismRA® Demonstrates Significantly Superior Outcomes Compared to Standard of Care in 3,348 Patient Analysis WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine announced data validating the clinical utility of the company’s PrismRA test for guiding treatment selection for rheumatoid arthritis (RA) patients. The latest publication in the … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–$TNDM #TNDM–Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study of adults living with type 2 diabetes who achieved improvement in all clinical endpoints with the use of the t:slim X2 insulin pump with Control-IQ technology.1 Presented today at the … [Read more…]

Primary endpoint met in high-risk carcinoma in situ (CIS) cohort with 71% complete response rate (CR) with a median duration of response of 26.6 months, a 53% CR rate at 24 months and a safety profile comparable to BCG alone This novel IL-15 superagonist N-803 – referred to as nogpendekin alfa inbakicept (NAI) in the … [Read more…]

BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Dave Mowry, Chief Executive Officer, and Greg Barker, Vice President, Corporate FP&A, will participate in a fireside chat at the Stephens Annual Investment Conference at 4:00 pm CT on Wednesday, November 16, 2022, at … [Read more…]

BRISBANE, Calif.–(BUSINESS WIRE)–Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that Dave Mowry, Chief Executive Officer, and J. Daniel Plants, Executive Chairperson, will participate in a fireside chat at the Stifel Healthcare Conference at 8:00 am ET on Tuesday, November 15, 2022, at the Lotte … [Read more…]

– Raymond F. Schinazi, Ph.D., to Step Down from Board of Directors and Continue as a Member of the Company’s Scientific Advisory Board (SAB) DURHAM, N.C.–(BUSINESS WIRE)–$DTIL #ARCUS–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Dr. … [Read more…]